Lightnews — Scholar-powered news

Sanjay Popat @drsanjaypopat.bsky.social · Sep 5

For those of you wondering why newer antibodies are now called -tugs -barts -migs and -ments not -mabs, this is the official @who.int INN explainer

tinyurl.com/49bxfn4t

1 4 8

Reposted by Sanjay Popat

BTOG @btog.bsky.social · Jul 31

🌍 Why do people who’ve never smoked get lung cancer?
Our first session dives into epidemiology, environmental aetiology, and early detection.
With @ruthstraussfdn.bsky.social‬
🧠 #BTOG2025 | 📍 London | 📅 13 Nov
🔗 www.btog.org/non-smo...
#LungCancer #LCSM #NonSmokingLungCancer

1 1

Reposted by Sanjay Popat

The OncoAlert Network 🚨 @oncoalert.bsky.social · May 26

The #ASCO25 #OncoAlertTOP10 Abstracts in #LungCancer 🫁 These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago 🇺🇸

@biagioricciutimd.bsky.social
‬ @stephenvliu.bsky.social
@drsanjaypopat.bsky.social
Ping
@drjnaidoo.bsky.social

9 17

Reposted by Sanjay Popat

Dr. Herbert Loong @herbloongmd.bsky.social · Apr 26

Thank you #LCS2025 in #KualaLumpur 🇲🇾 for hosting an informative & interactive lung cancer meeting! Always pleasure to meet colleagues who are keen to move our 🫁 field forward. #LCSM @apoddc @APCLC_2023

@stephanieplsaw @drdaviddwlee #BeungChulAhn #PJVoon #JenniferLeong @drsanjaypopat.bsky.social

1 2

Reposted by Sanjay Popat

Tom Newsom-Davis @tnewsomdavis.bsky.social · Apr 10

❗️FLAURA2 approved by NICE❗️

Already on BlueTeq!

Now an option for 1L EGFR+ pts

Worth familiarising yourself with the higher risk subgroups that seemed to better with this regimen

BTOG @btog.bsky.social · Apr 10

NICE has recommended Osimertinib with pemetrexed and platinum-based chemotherapy (based on the FLAURA2 trial) as an option for untreated advanced NSCLC in adults whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.

3 5

Sanjay Popat @drsanjaypopat.bsky.social · Apr 10

Great to see this important step for our EGFR mutant patients: FLAURA-2 approval by NICE. Interesting to note that the reimbursement (Blueteq form) allows a single cycle of chemo if clinically urgently indicated, but no access if PD on adjuvant osi. @btog.bsky.social @egfrpositiveuk.bsky.social

BTOG @btog.bsky.social · Apr 10

BTOG wishes to inform members of a new NICE release that has been published today.

Full details www.nice.org.uk/guidance/ind...

Project documents | Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328] | Guidance | NICE

www.nice.org.uk

2 2 5

Sanjay Popat @drsanjaypopat.bsky.social · Apr 5

Very important dataset and a set forward to potential ambulatory delivery in the future.

Dr. Herbert Loong @herbloongmd.bsky.social · Apr 5

Happy to share our recent #ESMOOpen paper on the #safety and #feasibility of #outpatient administration of #tarlatamab as part of the #DeLLphi300 study providing evidence that support less intensive monitoring at initiation of therapy. #LCSM 🫁 #SCLC 😀

doi.org/10.1016/j.es...

1 3

Reposted by Sanjay Popat

Tom Newsom-Davis @tnewsomdavis.bsky.social · Mar 13

HER2 mutated NSCLC increasingly important as a rest of new TKI show promising effectiveness in early phase trials

Riyaz Shah and I discuss these, and other HER2 targeted treatments

BTOG @btog.bsky.social · Mar 13

New Podcast Alert! BTOG Does ... HER2.

Featuring @tnewsomdavis.bsky.social, Dr Emma O'Dowd and Dr Riyaz Shah, listen wherever you get your podcasts (search 'BTOG') or online www.btog.org/btog-podcasts/ .

1 7

Sanjay Popat @drsanjaypopat.bsky.social · Mar 9

Very nice perspective from Drs Tannock, De Vries & colleagues @pmresearch-uhn.bsky.social in @thelancetoncol.bsky.social on dose optimization for oncology drugs: an area that @nihr.bsky.social should be evaluating, IMHO @nhsengland.bsky.social @bopa.org.uk

shorturl.at/aszUO

Dose optimisation to improve access to effective cancer medicines

Access to many cancer medicines on WHO's Essential Medicines List (EML) is restricted because of price, especially in low-income and middle-income countries (LMICs). Other cancer medicines that have b...

shorturl.at

3

Reposted by Sanjay Popat

Chloe Waterson @chloewaterson.bsky.social · Mar 5

Was really looking forward to this session and it didn't disappoint! Always find related questions the hardest to answer in clinic. Just a shame they had the graveyard slot!

@bopa.org.uk take note of the speakers, they would be great additions to annual conference agenda

#BTOG25

2 8

Reposted by Sanjay Popat

Gerry Hanna @gerryhanna.bsky.social · Mar 5

Well #BTOG25 that’s a wrap for 2025 from #Belfast

Thanks to @btog.bsky.social for 3 fantastic years in Belfast

It’s been an absolute pleasure to have the BTOG community over with us for the last 3 years 🙏

Here’s to next year in Edinburgh!
@drsanjaypopat.bsky.social
@tnewsomdavis.bsky.social

3 7

Reposted by Sanjay Popat

Jo Evans. @oncolojo.bsky.social · Mar 5

With the successful role out of the TLHC programme, we now have a growing cohort of stage 1 SCLC patients. Hopefully this will become even more common, and work needed to understand optimal patient management @drjnaidoo.bsky.social #BTOG25

4 12

Sanjay Popat @drsanjaypopat.bsky.social · Mar 5

Agree. A packed room for SCLC on the last day of a conference? Unheard of previously! Obviously all attending to listen to @annaminchom.bsky.social , @drjnaidoo.bsky.social ,& @stephenvliu.bsky.social!

@btog.bsky.social #BTOG25

Carles Escriu @carlesescriu.bsky.social · Mar 5

SCLC was indeed the star at #BTOG25. Looking forward to the benefit (and challenges) of novel therapeutic strategies.

Translational studies to aid patient selection will now be more needed than ever.

BTOG @btog.bsky.social · Mar 5

Welcome back for the last day of #BTOG25! The first session of the day will begin at 9.00 but refreshments are available from 8am! #LCSM

Today’s Prevention and Staging session is chaired by Alan Kirk and Emma O’Dowd with Graham Warren, Richard Lee, Luigi Ventura and Helen Liddicoat speaking.

5 13

Reposted by Sanjay Popat

Jo Evans. @oncolojo.bsky.social · Mar 5

@annaminchom.bsky.social on newer small cell therapeutic strategies and management of CRS and ICANS as specific TRAEs With thought around timings of dose delivery and education of AOS teams and patients, safely deliverable within the NHS

#BTOG25

1 7 8

Sanjay Popat @drsanjaypopat.bsky.social · Mar 5

Great job, team! @btog.bsky.social #BTOG25

Davidmcmahon @drdavidmcmahon.bsky.social · Mar 5

Excellent conference at #BTOG25 My pleasure to present our data on SCLC, Mesothelioma and resectable NSCLC from The Royal Marsden

2

Reposted by Sanjay Popat

Yvonne Diaz @yvonnediaz.bsky.social · Mar 5

Professor @drjnaidoo.bsky.social welcomed to the #BTOG25 stage as a Lung Cancer Legend & doesn’t disappoint. Lots of discussion on how we turn discussions on Small Cell Lung Cancer on its head. Lots of optimism in #SCLC coming from new standards & future treatments. #LCSM

7 17

Reposted by Sanjay Popat

DrLJ @drlaurajane.bsky.social · Mar 5

At #BTOG25 & I tringied by Matt’s comment on the fact that GP practices who request more chest X-rays have less stage III/IV #lungcaner disease? Read more here! www.respiratoryfutures.org.uk/features/dia...

Diagnosing Lung Cancer: X-rays & CT Scans | Respiratory Futures

Learn how chest x-rays and CT scans aid in diagnosing lung cancer and the role of primary care in early detection.

www.respiratoryfutures.org.uk

1 3

Reposted by Sanjay Popat

DrLJ @drlaurajane.bsky.social · Mar 5

We really need to make sure people know this!! It’s never too late to quit smoking. Treating tobacco dependence is cancer treatment! We would not let this survival benefit pass us by of this was a new oncology drug. #BTOG25

Chloe Waterson @chloewaterson.bsky.social · Mar 5

So what's the point in quitting smoking once you've already been diagnosed with cancer?

Quitting in the first 6 months could add extra years to survival!

#BTOG25

2 7

Reposted by Sanjay Popat

Chloe Waterson @chloewaterson.bsky.social · Mar 5

So what's the point in quitting smoking once you've already been diagnosed with cancer?

Quitting in the first 6 months could add extra years to survival!

#BTOG25

3 7

Reposted by Sanjay Popat

Jo Evans. @oncolojo.bsky.social · Mar 5

@stephenvliu.bsky.social on excitement in the Small Cell arena. PDL1/PD1 inhibition a practice changer, but so many potential game changers on the horizon from BITES To ADC, it’s exciting to see new drugs for an area of unmet need #BTOG25

5 14

Reposted by Sanjay Popat

Jo Evans. @oncolojo.bsky.social · Mar 5

@drjnaidoo.bsky.social on the limited stage small cell space and the excitement around CCRT-Durvalumab. EAMS currently open in England… #BTOG25

5 10

Reposted by Sanjay Popat

Jo Evans. @oncolojo.bsky.social · Mar 5

Small cell in never smokers. On the rise for unknow reasons and a different biology. Having recently encountered my first patient who’s a never smoker(and no alcohol or recreational drugs), with extensive stage disease this insight is fascinating @stephenvliu.bsky.social #BTOG25

2 6 27

Reposted by Sanjay Popat

Jo Evans. @oncolojo.bsky.social · Mar 4

@drsanjaypopat.bsky.social ! The OG!!! #BTOG25 @btog.bsky.social

1 3 6

Reposted by Sanjay Popat

BTOG @btog.bsky.social · Mar 5

We are delighted to announce that the 2025 BTOG Lifetime Achievement Award has been presented to Professor
Cindy Billingham.

The announcement was made by Professor Gary MIddleton and hosted at the 23nd BTOG Annual Conference in Belfast by Professor @drsanjaypopat.bsky.social

#BTOG25 #LCSM

2 9

Reposted by Sanjay Popat

Oncogene Cancer Research @oncogenecancer.bsky.social · Mar 5

Historic moment at #BTOG25 at last evening’s dinner where Professor @drsanjaypopat.bsky.social finished his 13 year tenure as BTOG Chair & heralded the great progress. The reigns (& clapper) hv now been handed to Dr @tnewsomdavis.bsky.social.
Patient advocates grateful for progress & keen for more

2 9